King Pharmaceuticals KG Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Leverage | ||||||
| Debt-to-equity | 1.5×— | 1.4×+1.3× | 1.2×— | 1.2×— | —— | |
| Debt-to-assets | 0.2×— | 0.2×+0.1× | 0.2×— | 0.2×— | —— | |
| Per Share | ||||||
| Book value per share | $15.66+919% | $22.38+1,236% | $18.57+1,039% | $32.38+1,712% | $1.54— | |
| Valuation | ||||||
| Market capitalization | $70.42M-71.3% | $79.28M— | $211.43M— | $248.69M— | —— | |
| Enterprise value | $184.93M-52.3% | $231.11M— | $347.1M— | $390.96M— | —— | |
| Price / sales | 1.6×-27.7× | 2.3×— | 8.4×— | 29.7×— | —— | |
| Price / book | 0.6×-1.1× | 0.6×— | 1.5×— | 1.7×— | —— | |
| EV / sales | 4.3×-42.1× | 6.8×— | 13.9×— | 46.7×— | —— |
Questions, answered.
- Where do King Pharmaceuticals's ratios come from?
- Every ratio is computed from King Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
